Revelation Biosciences, Inc.
REVBW 0.01 Stock Price Revelation Biosciences, Inc.

Home
  /  
Stock List  /  Revelation Biosciences, Inc.
Range:0.0134-0.0134Vol Avg:0Last Div:0Changes:0
Beta:0.15Cap:0.00BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Thu Jan 01 1970Empoloyees:9
CUSIP:76135L119CIK:0001810560ISIN:US76135L1199Country:US
CEO:Mr. James M. RolkeWebsite:https://www.revbiosciences.com
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.

Stock Details

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection StatusPowered by StackThrow